MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Fifth Disease (parvovirus B19)

Selected References:

  • Anderson LG. 1990. Human parvovirus B19. Pediatric Annuals 1990 19(9):509-513.
  • Bascietto F, et al. 2018. Outcomes associated with fetal parvovirus B19 infection: A systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018 Nov;52(5):569-576.
  • Bizjak G, et. al. 2009, Acute infection with parvovirus B19 in early pregnancy. Ultrasound Obstet Gynecol, 34: 234–235.
  • Chisaka H, et al 2006. Clinical manifestations and outcomes of parvovirus B19 infection during pregnancy in Japan. Tohoku J Exp Med. 209(4):277-283. PMID: 16864949 DOI: 10.1620/tjem.209.277
  • Committee on Infectious Disease. American Academy of Pediatrics: Parvovirus B 19, in 2003 Red Book: Report of the Committee on Infectious Disease, 26th edition, pp 459-461.
  • Crane J, et al. 2014. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can. 36(12):1107-16.
  • Daniilidis A, et al. 2014. Association of fetal loss with recent parvovirus infection and other demographic prognostic risk factors. J Obstet Gynaecol 34(1): 40-44.
  • DeJong EP, et. al. 2012. Intrauterine transfusion for parvovirus B19 infection: long-term neurodevelopmental outcome. Am J Obstet Gynecol 206(3):204.
  • de Jong EP, et. al. 2011, Parvovirus B19 infection in pregnancy: new insights and management. Prenat. Diagn., 31: 419–425.
  • Fairley CK, et al. 1995. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet 346(8986):1335-1337.
  • Gilbert GL. 2000. Parvovirus B19 infection and its significance in pregnancy. Commun Dis Intell. 24 Suppl:69-71. PMID: 10846815
  • Gillespie SM, et al. 1990. Occupational risk of human parvovirus B19 infection for school and daycare personnel during an outbreak of erythema infectiosum. JAMA 263:2061-2065.
  • Jordan JA. 2001. Placental cellular immune response in women infected with human parvovirus B19 during pregnancy. Clin Diagn. Lab Immunol 8(2):288-292.
  • Kailasam C. 2001. Congenital parvovirus B19 infection; experience of a recent epidemic. Fetal Diagn Ther. 16(1):18-22.
  • Kawabe A, et al. 2016. Placental abruption possibly due to parvovirus B19 infection. Springerplus 5(1): 1280.
  • Koga M. 2001. Human parvovirus B19 in cord blood of premature infants. Am J Perinatol. 18 (5):237-240.
  • Kostolansky S, et al 2021. Erythema Infectiosum. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK513309/. Accessed 01/2022.
  • Lassen J et. al. 2013. Parvovirus B19 infection in pregnancy and subsequent morbidity and mortality in offspring. Int. J. Epidemiol 42 (4): 1070-1076.
  • McCarter-Spaulding D. 2002. Parvovirus B19 in pregnancy. JOGNN. 31:107-112.
  • Nagel H, et al. 2007. Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection, Obstet Gynecol 109(1):42-7.
  • Ornoy A, et al. 2017. Parvovirus B19 infection during pregnancy and risks to the fetus. Birth Defects Res. 109(5):311-323. doi: 10.1002/bdra.23588.
  • Sailer DN, et al. 1993. Maternal serum biochemical markers in pregnancies with fetal parvovirus B19 infection. Prenat Diagn 12(6):467-741.
  • Soulie JC. 1995. Cardiac involvement in fetal parvovirus B19 infection. Pathol Biol Paris 43(5):416-419.
  • Staroselsky A, et al. 2009. Exposure to fifth disease in pregnancy. Can Fam Physician;55(12):1195-8. PMID: 20008596 PMCID: PMC2793222
  • The American College of Obstetricians and Gynecologists. 2015. Practice Bulletin. Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. Ob Gyn 125(6): 1510-1525.
  • Tolfvenstam T and Broliden K. 2009. Parvovirus B19 infection, Semin Fetal Neonatal Med 14(4):218-21.
  • Williams EJ, et al. 2013. Viral infections: contributions to late fetal death, stillbirth, and infant death. J Pediatr. 2013 Aug;163(2):424-8.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.